Skip to main content
News Icon

Europe is a top destination for many researchers

ImmunoSensation2 Scientist, Dr. Bernardo Franklin was feature in a Nature article entitled "Europe is a top destination for many researchers". The article interviewed scientists from different parts of the world who are working in the EU.

“Science is not a recognized profession in Brazil, where I come from,” says Bernardo Franklin, an immunologist at the University of Bonn in Germany. “In Germany, PhD students are given working contracts, with regulations that provide them with insurances, pension and other benefits, and protect them from exploitation and abusive supervisors.”

Publication

https://www.nature.com/articles/d41586-019-01570-3

Related news

Children in the lab at "Girls' and Boys' Day 2026"

News categories: Outreach

Girls' & Boys' Day at ImmunoSensation³

The annual "Girls' & Boys' Day" (former "Girls' day") sets out to introduce children and young addults to careers their respective gender is still underrepresented in. To celebrate this special day and offer insights into the work of a biomedical researcher, we welcomed students from all over Germany to our laboratories. Besides hands-on science, career options and perspectives in research were discussed.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry
Nora Möhn

News categories: Publication

New Findings on Immunotherapy for a Rare Brain Infection

Progressive multifocal leukoencephalopathy (PML) is a rare but very serious brain disease. It is caused by the reactivation of the widespread JC virus when the immune system is severely weakened. There is currently no targeted antiviral therapy available, which is why new treatment approaches are urgently needed. In recent years, so-called immune checkpoint inhibitors have been increasingly used; these “unlock” the immune system and reactivate the body’s own immune cells. The results were recently published in the journal JAMA Neurology.
View entry

Back to the news overview